These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 27434660)

  • 41. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.
    Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H;
    Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia.
    Dillon LW; Gui G; Ravindra N; Andrew G; Mukherjee D; Wong ZC; Huang Y; Gerhold J; Holman M; D'Angelo J; Miller J; Higgins J; Salk JJ; Auletta JJ; El Chaer F; Devine SM; Jimenez-Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Spellman SR; Zeger SL; Page KM; Hourigan CS
    JAMA Oncol; 2024 Aug; 10(8):1104-1110. PubMed ID: 38696205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
    Aydin S; Passera R; Scaldaferri M; Dellacasa CM; Poggiu M; Cattel F; Zallio F; Brunello L; Giaccone L; Dogliotti I; Busca A
    Int J Hematol; 2022 Dec; 116(6):883-891. PubMed ID: 35943684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
    Osone S; Imamura T; Kanayama T; Tsuma Y; Kawashima-Goto S; Nakatani T; Sugimoto A; Takai A; Miyachi M; Tamura S; Ishida H; Hosoi H
    J Pediatr Hematol Oncol; 2017 May; 39(4):e199-e202. PubMed ID: 27571118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FLT3-ITD positive acute myeloid leukemia: A retrospective analysis of the role of allogeneic transplant and allelic ratio in patient management.
    Taylor E; Morris K; Ellis M; Marlton P; Baveshi K; Clarey J; Irving I; Cochrane T; Kennedy G
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):426-430. PubMed ID: 29383835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
    Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
    Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.
    Qiu QC; Wang C; Bao XB; Yang J; Shen HJ; Ding ZX; Liu H; He J; Yao H; Chen SN; Li Z; Xue SL; Liu SB
    Hematology; 2018 Apr; 23(3):131-138. PubMed ID: 28876197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
    Loo S; Roberts AW; Anstee NS; Kennedy GA; He S; Schwarer AP; Enjeti AK; D'Rozario J; Marlton P; Bilmon IA; Taper J; Cull G; Tiley C; Verner E; Hahn U; Hiwase DK; Iland HJ; Murphy N; Ramanathan S; Reynolds J; Ong DM; Tiong IS; Wall M; Murray M; Rawling T; Leadbetter J; Rowley L; Latimer M; Yuen S; Ting SB; Fong CY; Morris K; Bajel A; Seymour JF; Levis MJ; Wei AH
    Blood; 2023 Dec; 142(23):1960-1971. PubMed ID: 37647654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
    Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
    Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITD
    Pandya BJ; Burns LJ; Wang T; Xie B; Touya M; Spalding J; Block A; Kuperman G; Young C
    Transplant Cell Ther; 2024 Jul; 30(7):683.e1-683.e13. PubMed ID: 38663769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
    Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O
    Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
    Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
    Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
    Labouré G; Dulucq S; Labopin M; Tabrizi R; Guérin E; Pigneux A; Lafarge X; Leguay T; Bouabdallah K; Dilhuydy MS; Duclos C; Lascaux A; Marit G; Mahon FX; Boiron JM; Milpied N; Vigouroux S
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1845-50. PubMed ID: 22766221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
    Pratz KW; Rudek MA; Smith BD; Karp J; Gojo I; Dezern A; Jones RJ; Greer J; Gocke C; Baer MR; Duong VH; Rosner G; Zahurak M; Wright JJ; Emadi A; Levis M;
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):300-306. PubMed ID: 31550496
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TKI Maintenance After Stem-Cell Transplantation for
    Gagelmann N; Wolschke C; Klyuchnikov E; Christopeit M; Ayuk F; Kröger N
    Front Immunol; 2021; 12():630429. PubMed ID: 33790903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
    Yalniz F; Abou Dalle I; Kantarjian H; Borthakur G; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Sasaki K; Daver N; DiNardo C; Pemmaraju N; Short NJ; Yilmaz M; Bose P; Naqvi K; Pierce S; Nogueras González GM; Konopleva M; Andreeff M; Cortes J; Ravandi F
    Am J Hematol; 2019 Sep; 94(9):984-991. PubMed ID: 31237017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.